Introduction
============

Marfan syndrome (MFS) is an autosomal dominant hereditary disease comprising a disorder of fibrous connective tissue involving the ocular, skeletal and cardiovascular systems ([@b1-mmr-16-05-7321]). According to the Ghent criteria, patients with malfunctions of at least two organ systems could be diagnosed with MFS ([@b2-mmr-16-05-7321]). Aortic root dilatation/dissection and lens dislocation were two cardinal manifestations to establish an unequivocal diagnosis of MFS in patients with positive family history. Due to the large clinical variability of MFS, and several other connective tissue disorders with comparable clinical features, distinguishing MFS from those similar syndromes is still challenging.

Increasing evidence indicates that heredity holds a key role in the development of MFS. It has been reported that MFS generally results from mutations in the human fibrillin-1 (*FBN1*) gene ([@b3-mmr-16-05-7321],[@b4-mmr-16-05-7321]). At present, \>3,000 mutations have been identified in relation to MFS. Most mutations are specific to a family with MFS, whereas \~10% of *FBN1* mutations are shared by different families ([@b5-mmr-16-05-7321]). Located at chromosome 15q-21.1 with 65 exons, the *FBN1* gene encodes a secreted 350 kDa glycoprotein ([@b6-mmr-16-05-7321]). Human FBN1 protein shares conserved sequences with other species. FBN1 protein constitutes extracellular microfibrils and controls the stability, as well as the microfibril assembly. Mutations within the *FBN1 gene* may disrupt microfibril formation, leading to abnormalities of fibrillin and eventually weakening the connective tissue ([@b7-mmr-16-05-7321]).

In the present study, the entire coding region of *FBN1* was analyzed, and a novel mutation in exon 14 of *FBN1* was identified in all affected members. The newly identified *FBN1* mutation in a Chinese family with MFS further emphasizes the important role of *FBN1* in the mechanism of MFS development. The present study not only expanded the mutation spectrum of *FBN1* resulting in MFS development in a Chinese family, but is also likely to aid understanding of the molecular pathogenesis and clinical diagnosis of *FBN1*-associated MFS.

Materials and methods
=====================

### Subjects

A family with MFS was recruited from the Shandong Provincial Hospital Affiliated to Shandong University (Jinan, China) ([Fig. 1](#f1-mmr-16-05-7321){ref-type="fig"}). This study was conducted in accordance to the tenets of The Declaration of Helsinki and was approved by the Institutional Review Boards of the Hospital of University of Electronic Science and Technology of China and Sichuan Provincial People\'s Hospital (Chengdu, China), and the Shandong Provincial Hospital Affiliated to Shandong University. A total of 383 ethnically matched, unrelated and normal healthy individuals were recruited from the Hospital of University of Electronic Science and Technology of China & Sichuan Provincial People\'s Hospital (255 males and 128 females; mean age at recruitment 55.26±8.78 years). These control individuals had no medical history associated with any related diseases. Written informed consent was obtained from all participants prior to the study.

### Clinical diagnosis

Two of the family members were diagnosed with MFS according to the revised Ghent criteria ([@b2-mmr-16-05-7321]). Non-consanguineous marriages were found in the family; clinical information of the affected family members is summarized in [Table I](#tI-mmr-16-05-7321){ref-type="table"}. All members of this family underwent complete physical, cardiovascular and ophthalmologic examinations. Unrelated healthy individuals also underwent the same examinations.

### Mutation screening

Genomic DNA samples were extracted from peripheral blood using a Blood DNA extraction kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The whole coding region of *FBN1* (NM_000138.4) was amplified by polymerase chain reaction (PCR) with 35 cycles (30 sec at 95°C for initial denaturation, 30 sec for annealing at different temperatures as shown in [Table II](#tII-mmr-16-05-7321){ref-type="table"}, and 30 sec at 72°C for extension), using a GeneAmp^®^ PCR system 9700 (Applied Biosystems; Thermo Scientific Inc.). Sequencing primers of all the exons were designed using Primer 5.0 (Premier Biosoft International, Palo Alto, CA, USA; [Table II](#tII-mmr-16-05-7321){ref-type="table"}). Amplified PCR products were purified and sequenced directly (BigDye Terminators Sequencing kit) with an Automated Genetic Analysis system 3130 (both from Applied Biosystems; Thermo Fisher Scientific, Inc.). Comparative amino acid sequence analysis of the human FBN1 protein was performed across different species using HomoloGene (<https://www.ncbi.nlm.nih.gov/homologene/?term=FBN1>). The potentially damaging effects of the mutation on the structure and function of FBN1 was predicted using SIFT (<http://sift.jcvi.org>) and PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>).

Results
=======

### Clinical findings

The parents and two daughters of a family from Shandong, China, were included in the present study ([Fig. 1](#f1-mmr-16-05-7321){ref-type="fig"}). Other relatives of this family were not willing to be tested and so additional clinical details were unattainable. Two affected patients (I:1 and II:2) exhibited similar clinical symptoms, including ectopialentis, myopia and strabismus ([Fig. 2](#f2-mmr-16-05-7321){ref-type="fig"} and [Table I](#tI-mmr-16-05-7321){ref-type="table"}). The left eye of the proband (I:1) underwent refractive lensectomy and vitrectomy combined with silicone oil tamponade after retinal detachment 2 years prior to the current study; following retinal re-attachment, silicone oil was removed 3 months later. The two patients both had the same facial and skeletal features, including arachnodactyly, flat feet and dilation of the aortic root ([Fig. 3](#f3-mmr-16-05-7321){ref-type="fig"} and [Table I](#tI-mmr-16-05-7321){ref-type="table"}). The proband had pectus carinatum and aortic aneurysm. The patient received Bentall surgery and underwent aortic arch replacement 5 years prior to the current study, as their aortic aneurysm ruptured and formed aortic dissection ([Fig. 4](#f4-mmr-16-05-7321){ref-type="fig"}). The other two members of the family had no features of MFS.

### Mutation screening of FBN1

Direct sequencing of the whole coding region of *FBN1* detected a novel missense mutation c.1708 T\>G (p.C570G), situated at nucleotide 570 in exon 14 of the coding region ([Fig. 5A](#f5-mmr-16-05-7321){ref-type="fig"}). This heterozygous mutation was detected in the two affected patients (I:1 and II:2) but was not found in the unaffected mother and daughter (I:2 and II:1) of the family and in the 383 ethnically matched healthy subjects. Therefore, c.1708 T\>G (p.C570G) cosegregated to the patients with MFS in this family. Multiple sequencing alignment of human FBN1 protein with various species revealed that the novel mutation occurred within a highly conserved region of the calcium binding epidermal growth factor-like (cbEGF) domain ([Fig. 5C](#f5-mmr-16-05-7321){ref-type="fig"}). This mutation is a T\>G transition, converting cysteine to glycine at amino acid 570 (p.C570G). This amino acid substitution in the FBN1 protein was predicted to be damaging by SIFT and PolyPhen-2.

Discussion
==========

It has been reported that MFS is mainly caused by mutations in the *FBN1 gene*, which was the first gene identified to cause MFS ([@b8-mmr-16-05-7321]). Of all the identified mutations in the *FBN1* gene, 38.6% result in a truncated FBN1 protein and 60.3% represent missense mutations across different ethnic groups ([@b9-mmr-16-05-7321]). *FBN1* mutations may cause abnormalities in the formation of microfibrils and fibrillin. As a result, connective tissues weaken ([@b10-mmr-16-05-7321]). A novel *FBN1* heterozygous missense mutation, c.1708 T\>G (p.C570G) was identified within a Chinese family associated with MFS in the present study.

FBN1 is an important component of microfibrils and is expressed in many human tissues, including in zonules, the cardiovascular system, cartilage, tendon and cornea. The protein serves a role in the formation of zonules and is secreted from ciliary bodies of non-pigmented cells ([@b11-mmr-16-05-7321]). FBN1 protein is composed of repeated modules, including cbEGF and transforming growth factor-1 binding protein-like domains, and is responsible for maintaining microfibers in an ordered arrangement ([@b12-mmr-16-05-7321],[@b13-mmr-16-05-7321]). The majority of identified missense mutations in *FBN1* are localized in cbEGF ([@b14-mmr-16-05-7321]). The mutated monomer of FBN1 could interfere with the polymerization of fibrillin and microfiber aggregation ([@b15-mmr-16-05-7321]). *FBN1* mutations within cbEGF modules may disrupt the stability of elastic fibers and render FBN1 susceptible to proteolysis. As a result, the transforming growth factor-β signaling activity that affects extracellular matrix formation may malfunction ([@b4-mmr-16-05-7321],[@b16-mmr-16-05-7321]).

In the present study, a novel c.1708 T\>G (p.C570G) heterozygous missense mutation of the *FBN1* gene was reported in a Chinese family with MFS. Three similar missense mutations: c.1709G\>A (p.C570Y) ([@b17-mmr-16-05-7321]), c.1709G\>C (p.C570S) ([@b18-mmr-16-05-7321]) and c.1709G\>C (p.C570R) ([@b19-mmr-16-05-7321]) have been reported in sporadic cases; however, clinical data in these studies were not obtained. In this pedigree, c.1708 T\>G (p.C570G) in *FBN1* was detected in the two patients with MFS (I:1 and II:2). The proband (I:1) initially came to Shandong Provincial Hospital to see an ophthalmologist and was found to suffer from ectopialentis, myopia and strabismus in both eyes. The proband and the affected daughter (II:2) had similar facial and skeletal features of MFS, including arachnodactyly, flat feet and dilation of aortic root. In addition, pectus carinatum, aortic dissection and retinal detachment were also detected in the proband. These findings suggested that the clinical manifestations of the patient with MFS became more evident with age. This mutation was not included in the Exome Aggregation Consortium dataset; c.1708 T\>G (p.C570G) of *FBN1* was not detected in the mother (I:2) and another daughter (II:1) of this family, or in the 383 unrelated normal controls during the mutation screening in the present study. This indicated that c.1708 T\>G (p.C570G) of *FBN1* cosegregated with affected MFS patients and may serve an important role in the pathogenesis of MFS development in this pedigree.

The p.C570G mutation of *FBN1* identified in this family with MFS resulted in a substitution of a highly conserved cysteine residue for glycine in a cbEGF domain of *FBN1*. This mutation is predicted to abolish one disulfide bond and thus affect the sixth conserved cysteine (C6) of the cbEGF domain; disulfide bonds are essential for the correct EGF-like domain structure. SIFT and PolyPhen-2 predictions indicated that this mutation is critical to protein function, supporting a possible pathogenic effect of this mutation. Evidence has revealed that most *FBN1* mutations are clustered in exons 24--32, a hot spot region associated with classic and severe forms of MFS ([@b17-mmr-16-05-7321],[@b20-mmr-16-05-7321]); mutations in exons 12--15 encoding cbEGF-like domains (C3-C6) cause a mild phenotype of MFS with possible late cardiovascular involvement ([@b21-mmr-16-05-7321]). Evidence from the present study consistently indicated that the identified heterozygous mutation, c.1708T\>G, is located at exon 14 and that this cysteine substitution detected in the proband resulted in pectus carinatum and aortic dissection. These two factors correlated with increasing age. However, evident symptoms were not detected in the young affected daughter (II:2), even though significant dilation of the aortic root was identified. Nevertheless, further functional analyses are required to confirm the role of *FBN1* and its underlying mechanisms in MFS.

In conclusion, a novel heterozygous mutation, c.1708 T\>G (p.C570G), in the *FBN1* gene was identified in a Chinese family associated with MFS. The results from the present study enrich the spectrum of MFS-associated mutations of *FBN1* and may aid presymptomatic molecular diagnosis of undetermined cases of MFS.
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![Pedigree of the family with Marfan syndrome. Solid symbols indicate affected patients, open symbols indicate unaffected subjects and arrow indicates the proband in this family. Squares represent males and circles represent females.](mmr-16-05-7321-g00){#f1-mmr-16-05-7321}

![Slitlamp photograph of the proband (I:1) and his daughter (II:2) in the family with MFS. (A) Left eye of the proband had ectopialentis. (B) Lensectomy and vitrectomy combined with silicone oil tamponade was performed for the right eye of the proband following retinal reattachment and silicone oil removed 3 months later. (C and D) Ectopialentis of the proband\'s daughter (II:2). (C) Lens nasal deviation occurred in her left eye and (D) nasal-inferior dislocation in her right eye. OS, oculus sinister (left eye); OD, oculus dexter (right eye).](mmr-16-05-7321-g01){#f2-mmr-16-05-7321}

![Arachnodactyly of the proband (I:1) and the affected daughter (II:2). (A) Proband (left) and his daughter (right) had (B) long fingers and (B) flat feet.](mmr-16-05-7321-g02){#f3-mmr-16-05-7321}

![CTA of the aortic vessels of the proband. (A) CTA confirmed the formation of aortic dissection. (B) CTA image of the artificial vessel of the proband after Bentall surgery. CTA, computed tomography angiogram.](mmr-16-05-7321-g03){#f4-mmr-16-05-7321}

![Representative chromatogram of *FBN1* sequence. (A) FBN1 has different functional regions and the p.C570G mutation occurs in the calcium binding EGF-like domain. (B) Normal sequence from an unaffected individual (I:2) (upper sequence), and a heterozygous T to G substitution at codon 570 from affected subjects (I:1 and II:2) (lower sequence). (C) Orthologous protein sequence alignment of FBN1 from different species, the mutated residue showing conservation of cysteine at codon 570 was shaded in red. EGF, epidermal growth factor; FBN1, fibrillin-1.](mmr-16-05-7321-g04){#f5-mmr-16-05-7321}

###### 

Clinical details of the patients with Marfan syndrome in the family.

  Characteristic                 Proband (I:1)                                                                                         Proband\'s daughter (II:2)
  ------------------------------ ----------------------------------------------------------------------------------------------------- ----------------------------
  Age (years)                    44                                                                                                    8
  Gender                         M                                                                                                     F
  Ectopialentis                  \+                                                                                                    \+
  Myopia                         \+                                                                                                    \+
  Strabismus                     +, exotropia                                                                                          +, exotropia
  Glaucoma                       −                                                                                                     −
  Retinal detachment             \+                                                                                                    −
  Height (cm)                    184                                                                                                   134
  Arm span (cm)                  186                                                                                                   137
  AS/H                           1.01                                                                                                  1.02
  Overgrowth of the long bones   \+                                                                                                    \+
  Arachnodactyly                 \+                                                                                                    \+
  Scoliosis                      −                                                                                                     −
  Pectus excavatum               −                                                                                                     −
  Pectus carinatum               \+                                                                                                    −
  Flatfeet                       \+                                                                                                    \+
  Mitral valve prolapse          −                                                                                                     −
  Aortic aneurysm                \+ (ruptured 5 years ago then formed aortic dissection; Bentall surgery was performed at that time)   −
  Aortic root dimension (mm)     25.0 (artificial vessel diameter)                                                                     29.1

M, male; F, female; AS, arm span; H, Height.

###### 

Primers used for mutation screening of the *FBN1* gene.

  Primer name    Primer sequence (5′-3′)     Product size (bp)   Annealing temperature (°C)
  -------------- --------------------------- ------------------- ----------------------------
  *FBN11&2F*     TCGGGGATTTGTCTCTGTGT        434                   59
  *FBN11&2R*     GCCCGTTGTTCTGGATCTTG                            
  *FBN13F*       ACCAACCCAGCATTGAGTCT        308                   60
  *FBN13R*       TTCTAAGGCTCCCCATGCAA                            
  *FBN14F*       TTGTGAGGGACCTGAGAACC        296                   59
  *FBN14R*       TTGCAGGAAAGAGGAAAGCC                            
  *FBN15F*       CAACTCCTGTGAGCTGTTGC        278                   60
  *FBN15R*       AAACATGCTGTGTCCCAGGT                            
  *FBN16F*       GTCCTTCCAGAGGACCACAA        228                   60
  *FBN16R*       CAGCTTTAGGTACCAGCATGTC                          
  *FBN17F*       GCATGATGGTTCCTGCTTTT        380                   60
  *FBN17R*       GCAGTCAGCGAAATTGTGAA                            
  *FBN18F*       TTCCAAATATTGTGATGGACAAA     448                   60
  *FBN18R*       ACAGGGTTTTTCTGGTCCAA                            
  *FBN19F*       GCTGTTTCCAGGGACATGAT        441                   60
  *FBN19R*       TTTATGGGAGGCAAAACGTC                            
  *FBN110F*      AGCCCCAGTGTGAAGTATGG        396                   60
  *FBN110R*      TTCCCTGGACGTCATCTCTT                            
  *FBN111F*      TGACTTCTGTGGGCCTATGA        300                   59
  *FBN111R*      TTAACTTGAACAATGCAAGAAAAA                        
  *FBN112F*      TTGTCACCAGACGACCTTTG        383                   60
  *FBN112R*      CCACCAAGTTTGGGGTAAGTT                           
  *FBN113F*      AAAAGGAACCCAGAAAGTCTTAGAA   295                   60
  *FBN113R*      CTTCCGGCATGGGTTATTTA                            
  *FBN114F*      GGAGGGAGGGGGAAATAAA         244                   60
  *FBN114R*      ACTGCAATGGAAGGAGAGGA                            
  *FBN115F*      GATCTTATTTGGATGAAAGTTAGCC   400                   59
  *FBN115R*      AGTCAGGTTTCCCAAACCAA                            
  *FBN116F*      TTCCCCATTTTCAAGGGTTA        294                   61
  *FBN116R*      CGTTTGTTACCATTGGGCTTT                           
  *FBN117F*      GGGGGTTCTCATCTGTTTGA        242                   60
  *FBN117R*      CAGTACGAGGGCATCTCCAT                            
  *FBN118F*      ACCAAGGGCAGGATCTACCT        188                   60
  *FBN118R*      ACCCACAAGAAAGCCTGATG                            
  *FBN119F*      CCTGTAGCTCCTAAGGTCATTACA    300                   60
  *FBN119R*      CTCCCAGCAATGAAAGAAGG                            
  *FBN120F*      CAAAGTTTGGGCCCTTTTTA        226                   59
  *FBN120R*      TGGCATTCCAAAAGATAGCA                            
  *FBN121F*      GGCCCAAGACTAGATTTTAGCA      243                   60
  *FBN121R*      TTTTGCAGGAAAAGCTGACA                            
  *FBN122F*      AATGTCAGCTTTTCCTGCAA        368                   59
  *FBN122R*      TGAAATACTAGGCTTCCCCTTT                          
  *FBN123F*      TGTCAGAACTGCAAAGTCTGG       204                   60
  *FBN123R*      GACAGCTTTATCCAGTCCGAGT                          
  *FBN124F*      TGCTATTCAGGCACCCTAGA        400                   59
  *FBN124R*      TGGAGTGTGTGTCTGTACCTGA                          
  *FBN125F*      AACAGAGTGTTGGCAGTTTGG       373                   60
  *FBN125R*      CTGAGATCATGAAAATGCATCC                          
  *FBN126&27F*   GACCTCCTGACTGCTTGCTC        494                   60
  *FBN126&27R*   CAAAGCTTCATGGAATCCTTCT                          
  *FBN128&29F*   GAGTGCTTGGTCTGGTGGAG        564                   61
  *FBN128&29R*   AGCGATGAAAACAAAACTCAGA                          
  *FBN130F*      GGGACAGACATCCAAACCAT        249                   62
  *FBN130R*      CAAAGCCTGGGCCCTAAAC                             
  *FBN131F*      CTCACTGAACAGTGGAACCAA       280                   59
  *FBN131R*      GCTCTCTTTGGAATGCTGGT        280                   59
  *FBN132F*      GAATCTTTCTATCACTGACCCAAAC                       
  *FBN132R*      TCGAGGGGAAAGTACTCAATG       325                   59
  *FBN133&34F*   CATTTGTGCTGAGCCTTTTTC       495                   60
  *FBN133&34R*   GAATGCCTGGCTTCTCTGAC                            
  *FBN135F*      TGCTGCACTGGAAAGTTGAT        231                   60
  *FBN135R*      AGTGGCTTCCCCATCAGTTA                            
  *FBN136F*      TGCCCAGATTGGTGTTAGAT        400                   59
  *FBN136R*      CAGGTCTGAGAAAAGGTATCTGTG                        
  *FBN137&38F*   AGATTGGGCCCTGTTCTTTT        819                   60
  *FBN137&38R*   TTGGGAATAAGGTCCCCTCT                            
  *FBN139&40F*   TCAGACGGGCAGAGTAACAA        496                   59
  *FBN139&40R*   CCATATTCTGGTTTTGCAGGT                           
  *FBN141F*      AGGCCATTCCAAAATGTGAA        249                   60
  *FBN141R*      TTGTGAGCTCTCTTCCTCTTTGT                         
  *FBN142F*      ATTTCCCACATGGCATCAC         300                   60
  *FBN142R*      TGCTTCCTTCGCTAAGACTGA                           
  *FBN143F*      CTATCCTCCCATCCCACCTT        273                   60
  *FBN143R*      CAGGGTGTTTGCACAGTTTG                            
  *FBN144F*      CACAGGGATCATGTGCTGTC        315                   60
  *FBN144R*      TCCACACCATGCCCTTTACT                            
  *FBN145F*      GGCTTTGTTGACTGGACACC        218                   62
  *FBN145R*      GTAGGCATGTCCAGCCTGTG                            
  *FBN146F*      GAGCTAGGATTACTCCTGAGAATGA   398                   59
  *FBN146R*      TCATGTTCAGATTGCCAAAGA                           
  *FBN147F*      GGCCTGGTGAACCCTAAAAT        247                   60
  *FBN147R*      TTCCTTTGCTGATGCACAAT                            
  *FBN148F*      TGCTGGGATTATGACATCTTTG      292                   60
  *FBN148R*      TTTTCCTCCAGGTTTCCAGA                            
  *FBN149F*      CCAGTGGGAACCTCTTCCTT        205                   60
  *FBN149R*      GACACCCGACACTCCTCATT                            
  *FBN150F*      TGATGTCTCCATCGTGTTTTG       208                   61
  *FBN150R*      ATTGAAAGCCCAAAGCCTTC                            
  *FBN151F*      GGAAAGCAACTGAAGGGTGT        263                 590
  *FBN151R*      GCCTACAGTCTTACTTACATCATGG                       
  *FBN152&53F*   GGAGAAGCTTGTAATGAATTGCT     594                   60
  *FBN152&53R*   AACTTATTTCAGTGCCATCTTGG                         
  *FBN154F*      TTTGGACACATTCCTGGTTTC       207                   60
  *FBN154R*      CAACCAATTGTTCCCAGGAT                            
  *FBN155F*      CCTTTTGTTGCTGTCCATGAT       249                   60
  *FBN155R*      AGGGAAGCTTTGAGGGACAT                            
  *FBN156F*      TCATACTCAACAGAGCAGAAGGA     363                   59
  *FBN156R*      CAAGAACTCAGAGCCCAGGT                            
  *FBN157F*      AAGGAACAAAGGGAGGGAAG        392                   60
  *FBN157R*      CAGTCATTACGGCATCTCCA                            
  *FBN158F*      CTGACATCCCCTTTGCCATA        277                   61
  *FBN158R*      TCCCTGCAAGTATTTTTGGAC                           
  *FBN159&60F*   CACTGAAGTGACCCCCTACA        600                   60
  *FBN159&60R*   TGAGGGGCAATGGTCAAT                              
  *FBN161&62F*   TGTTGGCTTGACTCAAATGC        600                   61
  *FBN161&62R*   CCTCCACAAGGATTCACCAG                            
  *FBN163F*      TGGTGGCTCTGCTTCTTTTT        178                   60
  *FBN163R*      GCCATGCATCTTGAGAGTGA                            
  *FBN164F*      AAGTGGCCAGATCCAATGTC        334                   60
  *FBN164R*      ACCATGACCAGGAAGAGCAC                            
  *FBN165F*      CATCTATGCTCCCCTTCTGC        243                   60
  *FBN165R*      TTCCACCACAGGAGACATCA                            
  *FBN166F*      GCAGCATAAGGCAGAAAATTG       583                   60
  *FBN166R*      TGATTCTGATTGGGGGAAAA                            

FBN1, fibrillin-1; F, forward; R, reverse; bp, base pair.

[^1]: Contributed equally
